RNA vaccine trial offers new hope for kids with recurrent brain cancer

NCT ID NCT07492316

Recruiting now ⭐️ VACCINE ⭐️ Sponsor: University of Florida Source: ClinicalTrials.gov ↗

First seen Mar 26, 2026 · Last updated May 13, 2026 · Updated 5 times

Summary

This study tests a personalized RNA vaccine for children and young adults (ages 3–39) whose medulloblastoma has returned after standard treatment. The vaccine is made from the patient's own tumor and aims to train the immune system to fight the cancer. The main goals are to see if the vaccine can be made safely and to find the best dose. Only 24 participants will be enrolled in this early-phase trial.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT MEDULLOBLASTOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

UF Health Shands Children's Hospital
RECRUITING

Gainesville, Florida, 32608, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

RECURRENT MEDULLOBLASTOMA